Teleophthalmology for Diabetic Retinopathy

Recruiting in Palo Alto (17 mi)

Overseen byYao Liu, MD, MS

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of Wisconsin, Madison

No Placebo Group

Trial Summary

What is the purpose of this trial?This study is being conducted to test the effectiveness of I-SITE (Implementation for Sustained Impact in Teleophthalmology), an implementation program to sustain increased diabetic eye screening rates using teleophthalmology in urban, multi-payer health systems.

Eligibility Criteria

This trial is for individuals with type 1 or type 2 diabetes who are part of an urban health system and have had diabetic eye screenings. Participants' medical records must include specific ICD-10 codes for diabetes and billing data for teleophthalmology services.

Inclusion Criteria

Billing data will be identified using teleophthalmology (CPT codes 92228 or 92250)

Eligible medical records will be identified using ICD-10 codes for diabetes type 1 or type 2

Identification of eligible records will be performed by clinic personnel at each health system who already have full access to their patient data as part of their employment, and regularly gather and report this type of data to health insurers as part of their clinical role

Participant Groups

The study tests the I-SITE program's effectiveness in maintaining high rates of diabetic eye screening through teleophthalmology, compared to usual care, within urban health systems that cater to multiple insurance payers.

1Treatment groups

Experimental Treatment

Group I: Usual Care Followed by I-SITE InterventionExperimental Treatment2 Interventions